Skip to main content

. 1992 Jul;55(7):630–631. doi: 10.1136/jnnp.55.7.630-a

A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease.

J L Montastruc, O Rascol, J M Senard, A Rascol

PMCID: PMC489186 PMID: 1386383

630

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Carter C. J., Lloyd K. G., Zivkovic B., Scatton B. Ifenprodil and SL 82.0715 as cerebral antiischemic agents. III. Evidence for antagonistic effects at the polyamine modulatory site within the N-methyl-D-aspartate receptor complex. J Pharmacol Exp Ther. 1990 May;253(2):475–482. [PubMed] [Google Scholar]
Carter C., Benavides J., Legendre P., Vincent J. D., Noel F., Thuret F., Lloyd K. G., Arbilla S., Zivkovic B., MacKenzie E. T. Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. II. Evidence for N-methyl-D-aspartate receptor antagonist properties. J Pharmacol Exp Ther. 1988 Dec;247(3):1222–1232. [PubMed] [Google Scholar]
Girault J. A., Halpain S., Greengard P. Excitatory amino acid antagonists and Parkinson's disease. Trends Neurosci. 1990 Aug;13(8):325–327. doi: 10.1016/0166-2236(90)90140-6. [DOI] [PubMed] [Google Scholar]
Klockgether T., Turski L. NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Ann Neurol. 1990 Oct;28(4):539–546. doi: 10.1002/ana.410280411. [DOI] [PubMed] [Google Scholar]
Reynolds I. J., Miller R. J. Ifenprodil is a novel type of N-methyl-D-aspartate receptor antagonist: interaction with polyamines. Mol Pharmacol. 1989 Nov;36(5):758–765. [PubMed] [Google Scholar]
Turski L., Bressler K., Rettig K. J., Löschmann P. A., Wachtel H. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature. 1991 Jan 31;349(6308):414–418. doi: 10.1038/349414a0. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES